Moderna
Search results
Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
At Vertex, the world’s most talented and passionate people come together to advance science and transform lives, and in return, we invest in them so they can grow and advance their own careers. If you’re ready to join us, browse open positions below.
Vertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.
Find the latest Vertex Pharmaceuticals Incorporated (VRTX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Latest Press Releases. Jul 02 2024. Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis. Jul 01 2024. Vertex to Announce Second Quarter 2024 Financial Results on August 1. Jun 21 2024.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and...
4 hari yang lalu · It wasn’t the biggest company, the most profitable or the fastest-growing. However, Vertex Pharmaceuticals Inc. placed near the top all of our financial metrics, making it the No.1 performer on the 2024 IW 50 Best U.S. Manufacturers list.
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions. Read More.
8 Dis 2023 · Vertex leads global development, manufacturing and commercialization of CASGEVY with support from CRISPR Therapeutics. In conjunction with the FDA approval of CASGEVY, Vertex will make a $200 million milestone payment to CRISPR, which will be capitalized and amortized to cost of sales.
